Skip to main content
x

Recent articles

Essa terminates an N-terminal journey

After beating "historical" Xtandi masofaniten fails to beat actual Xtandi.

FDA red and green lights: October 2024

October's US approvals included Scemblix, Vyloy and Itovebi, while Lumakras was delayed.

No SOS for Bayer's SOS1

The group goes after a KRAS-related target on which Boehringer recently gave up.

The month ahead: November’s upcoming events

Conferences ramp up, and ASH abstracts near.

Clouds loom for Novartis’s MorphoSys buy

Pelabresib is delayed, and Novartis writes off $800m of the €2.7bn purchase.

Triple meeting 2024 – Revolution shows selective KRAS promise

RMC-9805 looks more efficacious, and less toxic, than Astellas’s G12D degrader in pancreatic cancer.

Most Popular